Cybrexa Presents New Data for CBX-12 and CBX-13 at the AACR Virtual Annual Meeting II

Cybrexa Poster – CBX13 Cybrexa Poster – CBX12

This week we are presenting new preclinical data for our lead program, CBX-12 (alphalex-exatecan) and CBX-13 (alphalex-DM4) at the AACR Virtual Annual Meeting II.

Register for free and check out our e-posters at:

https://vcusa.sparx-ip.net/aacr2020ep/?view=1&searchfor=cybrexa&c=a&item=2020AB_6249

https://vcusa.sparx-ip.net/aacr2020ep/?view=1&searchfor=cybrexa&c=a&item=2020AB_6242

Cybrexa Therapeutics is Presenting, Speaking on a Panel at BIO Digital June 8-12, 2020

BIO Digital (June 8th-12th)

  • https://www.bio.org/events/bio-digital
  • Cybrexa company presentation will be available on demand starting on June 8
  • Cybrexa CEO Per Hellsund and VP, Corporate Development Keely Zipp are also speaking on the panel ‘Getting to the Tumor: Beyond the First Generation of Tumor Targeting Technologies’ available on demand June 8-12
  • Be sure to register and join us online: https://www.bio.org/events/bio-digital/sessions/620419

6TH Annual Immuno-oncology Innovation Forum (May 26-27th)

    • https://www.sachsforum.com/

Cybrexa is Presenting, Speaking on a Panel at the Sachs 6th Annual Digital Immuno-Oncology Innovation Forum, May 26-27, 2020

  • Cybrexa will present at the Sachs 6th Annual Digital Immuno-Oncology Innovation Forum that is being held May 26-27, 2020
  • Per Hellsund, CEO will also be a member of the ‘Latest Trends in C&G Therapeutics II: Focusing on Cancer Vaccines, Neo Antigens & Other Modalities’ panel which will be broadcast live on Wednesday, May 27, 2020 at 11am ET.
  • Access to this conference is free for investors via the link: https://www.sachsforum.com/6ioif-registration.html